Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 2
2011 1
2013 3
2014 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.
Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr; PENPACT-1 (PENTA 9/PACTG 390) Study Team. Yin DE, et al. Pediatrics. 2014 Oct;134(4):e1104-16. doi: 10.1542/peds.2014-0527. Pediatrics. 2014. PMID: 25266426 Free PMC article. Clinical Trial.
Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.
Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Harrison L, et al. AIDS Behav. 2013 Jan;17(1):193-202. doi: 10.1007/s10461-012-0197-y. AIDS Behav. 2013. PMID: 22584916 Free PMC article. Clinical Trial.
The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team. Klein N, et al. PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013. PLoS One. 2013. PMID: 24194841 Free PMC article. Clinical Trial.
HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team. Harrison L, et al. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671. J Acquir Immune Defic Syndr. 2015. PMID: 26322666 Free PMC article. Clinical Trial.
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
PENPACT-1 (PENTA 9/PACTG 390) Study Team; Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS. PENPACT-1 (PENTA 9/PACTG 390) Study Team, et al. Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31. Lancet Infect Dis. 2011. PMID: 21288774 Free PMC article. Clinical Trial.
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group. Cressey TR, et al. Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657. Clin Infect Dis. 2008. PMID: 18419497 Free PMC article. Clinical Trial.